The first CD19-targeted ADC therapy launched Phase 3 clinical joint development supported by Hillhouse

According to the China Drug Clinical Trial Registration and Information Publicity Platform, loncastuximab tesirine (Lonca), an antibody-drug conjugate (ADC) targeting CD19, has launched an international multi-center Phase 3 clinical trial in China for relapsed or refractory diffuse B.

The Phase 3 clinical trial launched in China this time was jointly applied by Linglu Pharmaceutical, ADC Therapeutics and other companies

Screenshot source: Drug Clinical Trial Registration and Information Publicity Platform

Publicly available data show that Lonca designed a humanized anti-CD19 monoclonal antibody conjugated to a unique cytotoxin called a pyrrolobenzodiazepine (PBD) dimer

CD19 is an antigen widely expressed in B-cell cancers.

In April 2021, the U.

The approval was based on the results of a single-arm Phase 2 clinical trial called LOTIS-2, which showed that Lonca achieved an overall response rate (ORR) of 48.

According to the China Drug Clinical Trial Registration and Information Publicity Platform, Lonca launched a phase 3 randomized study in patients with relapsed or refractory diffuse large B-cell lymphoma in China, aiming to evaluate the candidate drug in combination with Rituxan Efficacy of ximab versus standard immunochemotherapy

In addition, Lonca is conducting a Phase 2, open-label, single-arm study in China evaluating efficacy and safety in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

It is hoped that the clinical research of Lonca in China will proceed smoothly and be approved as soon as possible, bringing new treatment options to more Chinese patients